Treatment Registry
TR-0610 ActiveRecorded September 2, 2026

Brand semaglutide

Sold by eMed · Injection, pen · every brand semaglutide record

What you actually pay

Per month

$299.98

Medication · Prescription medication (paid only if approved)$149.99
Required membership$149.99

Added from the figures recorded below.

Price

TermPer monthCharged today
Prescription medication (paid only if approved)

Prescription Medication From $149.99 Per month Paid only if approved.

source

Per month$149.99Charged today$149.99
Visit eMed

We earn nothing from this link. eMed has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.

History

One reading so far. A price history appears here after the next verification pass.

  • September 2, 2026Entry added to the register

Sourcing and terms

StatesNot disclosed as of September 3, 2026
PrescriberAsynchronous review
MembershipRequired. $149.99 per month. “eMed's Membership Fee $149.99 Per month”

Not yet checked: pharmacy, cancellation and consult fee.

Recorded from emed.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. September 2, 2026This is the clearest example of the two-fee trap the brief warns about, except eMed discloses BOTH figures separately on the same pricing block: 'Application & Screening $49 One-time fee', then 'Prescription Medication From $149.99 Per month (Paid only if approved)', then, as its own separate line, 'eMed's Membership Fee $149.99 Per month.' So a member on the medication pays roughly $49 once plus $149.99/mo for the drug plus another $149.99/mo membership fee — total ~$300/mo, not $149.99. Medication is Wegovy (brand semaglutide), offered as both the injection pen and a newly launched once-daily Wegovy pill (oral); no separate price is shown for the pill. No cancellation/subscription-termination language was found on any crawled page — only a no-returns/no-refunds policy for dispensed products.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0610
Readings
1

Related records

Brand semaglutide at a similar price

The records either side of this one in the recorded spread. Not a ranking, and not a recommendation — a position among 67 records of the same molecule.

Cite this entry

Treatment Registry. (2026). eMed brand semaglutide (TR-0610). Last verified September 2, 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0610

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.